These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 33387637)
1. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. Wasan H; Singh D; Kh R Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Fabbri M; Rosa MM; Abreu D; Ferreira JJ Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease. Müller T Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. Cattaneo C; Jost WH; Bonizzoni E J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253 [TBL] [Abstract][Full Text] [Related]
11. Safinamide for symptoms of Parkinson's disease. Müller T Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740 [TBL] [Abstract][Full Text] [Related]
12. Safinamide for the treatment of Parkinson's disease. Dézsi L; Vécsei L Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154 [TBL] [Abstract][Full Text] [Related]
13. Safinamide: A Review in Parkinson's Disease. Blair HA; Dhillon S CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399 [TBL] [Abstract][Full Text] [Related]
14. Safinamide for the treatment of Parkinson's disease. Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164 [TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Müller T; Foley P Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574 [TBL] [Abstract][Full Text] [Related]
16. Current status of safinamide for the drug portfolio of Parkinson's disease therapy. Müller T Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. Stocchi F; Torti M Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951 [TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. Perez-Lloret S; Rascol O Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427 [TBL] [Abstract][Full Text] [Related]
19. Real life evaluation of safinamide effectiveness in Parkinson's disease. Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484 [TBL] [Abstract][Full Text] [Related]